Madrigal Pharmaceuticals ... (MDGL)
Madrigal Pharmaceuticals Statistics
Share Statistics
Madrigal Pharmaceuticals has 21.81M shares outstanding. The number of shares has increased by 9.61% in one year.
Shares Outstanding | 21.81M |
Shares Change (YoY) | 9.61% |
Shares Change (QoQ) | 0.45% |
Owned by Institutions (%) | 99.99% |
Shares Floating | 18.61M |
Failed to Deliver (FTD) Shares | 9 |
FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 4.08M, so 18.72% of the outstanding shares have been sold short.
Short Interest | 4.08M |
Short % of Shares Out | 18.72% |
Short % of Float | 22.21% |
Short Ratio (days to cover) | 10.54 |
Valuation Ratios
The PE ratio is -14.09 and the forward PE ratio is -24.13. Madrigal Pharmaceuticals's PEG ratio is -1.47.
PE Ratio | -14.09 |
Forward PE | -24.13 |
PS Ratio | 36.44 |
Forward PS | 1.8 |
PB Ratio | 8.7 |
P/FCF Ratio | -14.36 |
PEG Ratio | -1.47 |
Enterprise Valuation
Madrigal Pharmaceuticals Inc. has an Enterprise Value (EV) of 4.34B.
EV / Earnings | -9.32 |
EV / Sales | 24.1 |
EV / EBITDA | -8.72 |
EV / EBIT | -8.72 |
EV / FCF | -9.5 |
Financial Position
The company has a current ratio of 6.1, with a Debt / Equity ratio of 0.
Current Ratio | 6.1 |
Quick Ratio | 5.9 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0.13 |
Cash Flow / Debt | -463.45 |
Interest Coverage | 33.94 |
Financial Efficiency
Return on equity (ROE) is -0.62% and return on capital (ROIC) is -65.91%.
Return on Equity (ROE) | -0.62% |
Return on Assets (ROA) | -0.45% |
Return on Capital (ROIC) | -65.91% |
Revenue Per Employee | $341,160.98 |
Profits Per Employee | $-882,371.21 |
Employee Count | 528 |
Asset Turnover | 0.17 |
Inventory Turnover | 0.18 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 35.82% in the last 52 weeks. The beta is -0.38, so Madrigal Pharmaceuticals's price volatility has been lower than the market average.
Beta | -0.38 |
52-Week Price Change | 35.82% |
50-Day Moving Average | 321.47 |
200-Day Moving Average | 276.61 |
Relative Strength Index (RSI) | 53.03 |
Average Volume (20 Days) | 413.37K |
Income Statement
In the last 12 months, Madrigal Pharmaceuticals had revenue of 180.13M and earned -465.89M in profits. Earnings per share was -21.9.
Revenue | 180.13M |
Gross Profit | 173.9M |
Operating Income | -497.88M |
Net Income | -465.89M |
EBITDA | -497.88M |
EBIT | -497.88M |
Earnings Per Share (EPS) | -21.9 |
Balance Sheet
The company has 100.02M in cash and 983K in debt, giving a net cash position of 99.04M.
Cash & Cash Equivalents | 100.02M |
Total Debt | 983K |
Net Cash | 99.04M |
Retained Earnings | -1.8B |
Total Assets | 1.07B |
Working Capital | 885.82M |
Cash Flow
In the last 12 months, operating cash flow was -455.57M and capital expenditures -1.46M, giving a free cash flow of -457.03M.
Operating Cash Flow | -455.57M |
Capital Expenditures | -1.46M |
Free Cash Flow | -457.03M |
FCF Per Share | -21.48 |
Margins
Gross margin is 96.54%, with operating and profit margins of -276.39% and -258.64%.
Gross Margin | 96.54% |
Operating Margin | -276.39% |
Pretax Margin | -258.64% |
Profit Margin | -258.64% |
EBITDA Margin | -276.39% |
EBIT Margin | -276.39% |
FCF Margin | -253.72% |
Dividends & Yields
MDGL does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -6.41% |
FCF Yield | -6.13% |
Analyst Forecast
The average price target for MDGL is $383.5, which is 12.2% higher than the current price. The consensus rating is "Buy".
Price Target | $383.5 |
Price Target Difference | 12.2% |
Analyst Consensus | Buy |
Analyst Count | 13 |
Stock Splits
The last stock split was on Jul 25, 2016. It was a backward split with a ratio of 1:35.
Last Split Date | Jul 25, 2016 |
Split Type | backward |
Split Ratio | 1:35 |
Scores
Altman Z-Score | 12.97 |
Piotroski F-Score | 4 |